Drug profile

The FDA adverse-event record for Mirtazapine Transdermal Ointment

26 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Mirtazapine Transdermal Ointment. Species, reactions, and outcomes follow.

#1560 of 2,679
by report volume (all drugs)
26
adverse-event reports
42.3%
death-coded share
Cat
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Mirtazapine Transdermal Ointment ranks #1543 of 2679 by total reports (26). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1543
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Mirtazapine Transdermal Ointment has 26 reports now versus 25 in that prior snapshot: 1 more (4.0%).

Report change
+1
Death-coded reports
+0
Death-coded share
−1.7 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Mirtazapine Transdermal Ointment changes

Signature read: Mirtazapine Transdermal Ointment's 42.3% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
26
Total Reports
11
Deaths Reported
42.3%
Death-coded share of reports

Active Ingredients

Mirtazapine Transdermal Ointment

Administration Routes

TopicalUnknownTransdermalOther

Species Affected

Cat 25
Dog 1

Most Affected Breeds

Domestic Shorthair 19
Ragdoll 2
Domestic Longhair 2
Russian 1
Siamese 1
Bulldog - French 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 9
Death by euthanasia 8
Anorexia 6
Vomiting 6
Hiding 5
Not eating 5
Vocalisation 4
Behavioural disorder NOS 4
Abnormal radiograph finding 4
Hyperglycaemia 4
Diarrhoea 4
Other abnormal test result NOS 3

Outcome Breakdown

Euthanized
8 (30.8%)
Ongoing
8 (30.8%)
Recovered/Normal
4 (15.4%)
Died
3 (11.5%)
Outcome Unknown
3 (11.5%)

Mirtazapine Transdermal Ointment: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Mirtazapine Transdermal Ointment (#1560 of 2,679 by report volume); death-coded 42.3%. PlainBreed drug row · death-coded share stamp 42.3% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →